Vanguard Group
CHRS icon

Vanguard Group’s Coherus Oncology CHRS Stock Holding History

Vanguard Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.2M Sell
10,028,893
-292,214
-3% -$426K ﹤0.01% 2781
2025
Q3 		$16.9M Sell
10,321,107
-249,408
-2% -$277K ﹤0.01% 2708
2025
Q2 		$7.73M Sell
10,570,515
-581,390
-5% -$502K ﹤0.01% 3038
2025
Q1 		$9M Sell
11,151,905
-2,471
-0% -$2.84K ﹤0.01% 2901
2024
Q4 		$15.4M Sell
11,154,376
-156,306
-1% -$175K ﹤0.01% 2722
2024
Q3 		$11.8M Buy
11,310,682
+708,293
+7% +$971K ﹤0.01% 2873
2024
Q2 		$18.3M Buy
10,602,389
+522,835
+5% +$1.05M ﹤0.01% 2613
2024
Q1 		$24.1M Sell
10,079,554
-277,858
-3% -$684K ﹤0.01% 2508
2023
Q4 		$34.5M Buy
10,357,412
+575,285
+6% +$1.54M ﹤0.01% 2348
2023
Q3 		$36.6M Buy
9,782,127
+932,476
+11% +$4.31M ﹤0.01% 2278
2023
Q2 		$37.8M Buy
8,849,651
+2,992,451
+51% +$17.7M ﹤0.01% 2313
2023
Q1 		$40.1M Buy
5,857,200
+41,318
+0.7% +$321K ﹤0.01% 2269
2022
Q4 		$46.1M Buy
5,815,882
+587,181
+11% +$4.52M ﹤0.01% 2220
2022
Q3 		$50.2M Buy
5,228,701
+345,286
+7% +$3.49M ﹤0.01% 2185
2022
Q2 		$35.4M Buy
4,883,415
+146,314
+3% +$1.27M ﹤0.01% 2357
2022
Q1 		$61.2M Buy
4,737,101
+189,572
+4% +$2.41M ﹤0.01% 2206
2021
Q4 		$72.6M Buy
4,547,529
+33,228
+0.7% +$581K ﹤0.01% 2146
2021
Q3 		$72.5M Buy
4,514,301
+38,697
+0.9% +$567K ﹤0.01% 2161
2021
Q2 		$61.9M Buy
4,475,604
+214,504
+5% +$3.04M ﹤0.01% 2249
2021
Q1 		$62.3M Buy
4,261,100
+132,165
+3% +$2.24M ﹤0.01% 2194
2020
Q4 		$71.8M Buy
4,128,935
+262,406
+7% +$4.67M ﹤0.01% 2013
2020
Q3 		$70.9M Buy
3,866,529
+76,467
+2% +$1.42M ﹤0.01% 1845
2020
Q2 		$67.7M Buy
3,790,062
+663,453
+21% +$11.2M ﹤0.01% 1848
2020
Q1 		$50.7M Buy
3,126,609
+47,906
+2% +$885K ﹤0.01% 1863
2019
Q4 		$55.4M Buy
3,078,703
+150,309
+5% +$2.77M ﹤0.01% 2057
2019
Q3 		$59.3M Sell
2,928,394
-30,189
-1% -$603K ﹤0.01% 1990
2019
Q2 		$65.4M Buy
2,958,583
+87,091
+3% +$1.51M ﹤0.01% 1966
2019
Q1 		$39.2M Buy
2,871,492
+105,380
+4% +$1.41M ﹤0.01% 2210
2018
Q4 		$25M Buy
2,766,112
+83,311
+3% +$964K ﹤0.01% 2347
2018
Q3 		$44.3M Buy
2,682,801
+406,520
+18% +$7.21M ﹤0.01% 2204
2018
Q2 		$31.9M Buy
2,276,281
+213,759
+10% +$3.06M ﹤0.01% 2355
2018
Q1 		$22.8M Buy
2,062,522
+182,074
+10% +$1.99M ﹤0.01% 2445
2017
Q4 		$16.5M Sell
1,880,448
-587,118
-24% -$6.29M ﹤0.01% 2572
2017
Q3 		$32.9M Buy
2,467,566
+212,099
+9% +$2.81M ﹤0.01% 2262
2017
Q2 		$32.4M Buy
2,255,467
+46,223
+2% +$889K ﹤0.01% 2239
2017
Q1 		$46.7M Buy
2,209,244
+1,039,402
+89% +$25.6M ﹤0.01% 2042
2016
Q4 		$32.9M Buy
1,169,842
+140,141
+14% +$3.92M ﹤0.01% 2179
2016
Q3 		$27.6M Buy
1,029,701
+21,403
+2% +$584K ﹤0.01% 2216
2016
Q2 		$17M Buy
1,008,298
+352,103
+54% +$6.61M ﹤0.01% 2400
2016
Q1 		$13.9M Buy
656,195
+40,576
+7% +$665K ﹤0.01% 2442
2015
Q4 		$14.1M Buy
615,619
+19,012
+3% +$489K ﹤0.01% 2454
2015
Q3 		$12M Buy
596,607
+66,950
+13% +$2.04M ﹤0.01% 2511
2015
Q2 		$15.3M Buy
529,657
+354,114
+202% +$8.95M ﹤0.01% 2470
2015
Q1 		$5.37M Buy
175,543
+103,861
+145% +$2.68M ﹤0.01% 2964
2014
Q4 		$1.17M Buy
+71,682
New +$1.01M ﹤0.01% 3475

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Vanguard Group's CHRS Position: Q4 2025 in Review

Vanguard Group reduced its Coherus Oncology (CHRS) stake by 2.8% in Q4 2025, selling an estimated $426K and leaving 10,028,893 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2781.

Vanguard Group first reported a position in CHRS in Q4 2014 and has held it in 45 quarters since. The position peaked at $72.6M in Q4 2021. 127 funds tracked by Wall St. Rank hold CHRS as of Q4 2025.

  • Vanguard Group held 10,028,893 shares of Coherus Oncology worth $14.2M as of Q4 2025.
  • Vanguard Group sold 292,214 Coherus Oncology shares in Q4 2025, an estimated $426K.
  • Coherus Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2781 holding.
  • Vanguard Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 45 quarters since.
  • Vanguard Group's Coherus Oncology position peaked at $72.6M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.